



**MEDINEX LIMITED**

**Condensed Interim Financial Statements  
For the six months ended 30 September 2022**

## Table of Contents

A.	Condensed interim consolidated statement of profit or loss and other comprehensive income .....	3
B.	Condensed interim statements of financial position.....	5
C.	Aggregate amount of group's borrowing and debt securities.....	7
D.	Condensed interim statements of changes in equity .....	8
E.	Condensed interim consolidated statement of cash flows.....	11
F.	Notes to the condensed interim consolidated financial statements .....	13
G.	Other information required pursuant to Appendix 7C of the Catalist Rules .....	28

**A. Condensed interim consolidated statement of profit or loss and other comprehensive income**

	Note	Group		Change %
		6 months ended		
		30 September 2022 S\$'000	30 September 2021 S\$'000	
Revenue	4.1	6,486	5,806	11.72
<b>Other item of income</b>				
Other income		378	1,062	(64.41)
<b>Item of expense</b>				
Changes in inventories		(15)	(153)	(90.49)
Inventories and consumables		(1,788)	(1,538)	16.24
Employee benefits expense		(2,545)	(2,048)	24.25
Depreciation and amortisation expenses		(401)	(299)	34.26
Loss allowance on trade receivables		(18)	(19)	(4.28)
Other expenses		(1,213)	(488)	148.59
Finance costs		(35)	(45)	(21.03)
Share of results of joint venture, net of tax		70	10	615.83
Profit before income tax	6	919	2,288	(59.85)
Income tax expense	7	(208)	(192)	8.50
Profit for the financial period, representing total comprehensive income for the financial period		711	2,096	(66.10)

**A. Condensed interim consolidated statement of profit or loss and other comprehensive income (cont'd)**

		Group		
		6 months ended		
Note	30 September 2022	30 September 2021	Change	
	S\$'000	S\$'000	%	
<b>Other comprehensive income</b>				
Foreign currency translation differences	(5)	(6)	(20.65)	
Other comprehensive income for the financial period, net of tax	(5)	(6)	(20.65)	
Total comprehensive income for the financial period	706	2,090	(66.24)	
Profit attributable to:				
Owners of the Company	661	2,052	(67.80)	
Non-controlling interests	50	44	13.26	
	711	2,096	(66.08)	
Profit and total comprehensive income attributable to:				
Owners of the Company	656	2,046	(67.94)	
Non-controlling interests	50	44	13.00	
	706	2,090	(66.24)	
Earnings per share (cents)				
- Basic and diluted	9	0.50	1.56	(68.05)

N.M. - not meaningful

## B. Condensed interim statements of financial position

	Note	Group		Company	
		30-Sep-22	31-Mar-22	30-Sep-22	31-Mar-22
		S\$'000	S\$'000	S\$'000	S\$'000
<b>ASSETS</b>					
<b>Non-current assets</b>					
Plant and equipment	13	230	256	37	41
Right-of-use assets		962	865	-	-
Intangible assets	12	9,597	6,686	-	-
Investment in subsidiaries		-	-	13,597	10,596
Investment in joint venture		278	208	195	195
Financial assets at fair value through profit or loss ("FVTPL")	11	4,959	5,573	4,959	5,572
		16,026	13,588	18,788	16,404
<b>Current assets</b>					
Inventories		469	484	-	-
Trade and other receivables		1,587	2,121	389	207
Contract assets		19	63	-	-
Prepayments		117	386	62	426
Fixed deposit		516	516	-	-
Cash and bank balances		3,917	5,823	825	3,067
		6,625	9,393	1,276	3,700
Total assets		22,651	22,981	20,064	20,104
<b>EQUITY AND LIABILITIES</b>					
<b>Equity</b>					
Share capital		14,571	14,163	14,571	14,163
Other reserve		(1,348)	(1,540)	600	408
Foreign currency translation reserve		(11)	(6)	-	-
Retained earnings		4,182	4,636	2,344	2,802
<b>Equity attributable to owners of the parent</b>		17,394	17,253	17,515	17,373
Non-controlling interests		273	223	-	-
<b>Total equity</b>		17,667	17,476	17,515	17,373

**B. Condensed interim statements of financial position (cont'd)**

	Note	Group		Company	
		30-Sep-22	31-Mar-22	30-Sep-22	31-Mar-22
		S\$'000	S\$'000	S\$'000	S\$'000
<b>Non-current liabilities</b>					
Deferred tax liabilities		37	37	-	-
Lease liabilities		500	418	-	-
Other Payable		-	-	1,416	1,735
Bank borrowings	14	1,527	1,779	-	-
Provisions		32	31	-	-
		<u>2,096</u>	<u>2,265</u>	<u>1,416</u>	<u>1,735</u>
<b>Current liabilities</b>					
Trade and other payables		1,333	1,470	1,132	986
Lease liabilities		420	412	-	-
Contract liabilities		204	434	-	-
Bank borrowings	14	496	496	-	10
Current income tax payable		435	428	-	-
		<u>2,888</u>	<u>3,240</u>	<u>1,132</u>	<u>996</u>
<b>Total liabilities</b>		<u>4,984</u>	<u>5,505</u>	<u>2,548</u>	<u>2,731</u>
<b>Total equity and liabilities</b>		<u>22,651</u>	<u>22,981</u>	<u>20,064</u>	<u>20,104</u>

C. Aggregate amount of group's borrowing and debt securities

**Amount repayable in one year or less, or on demand**

As at 30-Sept-22			As at 31-Mar-22		
Secured		Unsecured	Secured		Unsecured
S\$'000		S\$'000	S\$'000		S\$'000
2		496	2		496

**Amount repayable after one year**

As at 30-Sept-22			As at 31-Mar-22		
Secured		Unsecured	Secured		Unsecured
S\$'000		S\$'000	S\$'000		S\$'000
-		1,527	-		1,779

**Details of any collaterals**

The Group's obligations under finance leases are secured on the plant and equipment purchased under finance lease arrangements.

D. Condensed interim statements of changes in equity

The Group		Share capital	Other reserves	Foreign currency translation reserve	Retained earnings	Equity attributable to owners of the parent	Non-controlling interests	Total equity
	Note	S\$'000	S\$'000	S\$'000	S\$'000	S\$'000	S\$'000	S\$'000
Balance at 1 April 2022		14,163	(1,540)	(6)	4,636	17,253	223	17,476
Profit for the financial period		-	-	-	661	661	50	711
<b>Total comprehensive income for the financial period</b>		-	-	-	661	661	50	711
<b>Contributions by and distribution to owners</b>								
Share-based payments		-	600	-	-	600	-	600
Issue new share		408	(408)	-	-	-	-	-
Foreign currency translation		-	-	(5)	-	(5)	-	(5)
Dividends		-	-	-	(1,115)	(1,115)	-	(1,115)
<b>Total transactions with owners</b>		408	192	(5)	(1,115)	(520)	-	(520)
<b>Transactions with non-controlling interest</b>								
Acquisition of subsidiaries		-	-	-	-	-	-	-
Dividends		-	-	-	-	-	-	-
<b>Total transactions with non-controlling interest</b>		-	-	-	-	-	-	-
Balance at 30 September 2022		14,571	(1,348)	(11)	4,182	17,394	273	17,667



D. Condensed interim statements of changes in equity (cont'd)

The Group		Share capital	Other reserves	Foreign currency translation reserve	Retained earnings	Equity attributable to owners of the parent	Non-controlling interests	Total equity
	Note	S\$'000	S\$'000	S\$'000	S\$'000	S\$'000	S\$'000	S\$'000
Balance at 1 April 2021		14,163	(1,540)	1	4,034	16,658	269	16,927
Profit for the financial period		-	-	-	2,052	2,052	44	2,096
<b>Total comprehensive income for the financial period</b>		-	-	-	2,052	2,052	44	2,096
<b>Contributions by and distribution to owners</b>								
Share-based payments		-	-	-	-	-	-	-
Foreign currency translation		-	-	(6)	-	(6)	-	(6)
Dividends		-	-	-	(1,102)	(1,102)	(135)	(1,237)
<b>Total transactions with owners</b>		-	-	(6)	(1,102)	(1,108)	(135)	(1,243)
<b>Transactions with non-controlling interest</b>								
Acquisition of subsidiaries		-	-	-	-	-	-	-
Dividends		-	-	-	-	-	-	-
<b>Total transactions with non-controlling interest</b>		-	-	-	-	-	-	-
Balance at 30 September 2021		14,163	(1,540)	(5)	4,984	17,602	178	17,780

D. Condensed interim statements of changes in equity (cont'd)

Company	Note	Share capital S\$'000	Other reserves S\$'000	Retained earnings S\$'000	Total equity S\$'000
Balance as 1 April 2022		14,163	408	2,803	17,374
<b>Profit for the financial year</b>		-	-	656	656
<b>Total comprehensive income for the financial year</b>		-	-	656	656
<b>Contributions by and distributions to owners</b>					
Share-based payments		-	600	-	600
Issue new share		408	(408)		
Dividends		-		(1,115)	(1,115)
<b>Total transactions with owners</b>		408	192	(1,115)	(515)
Balance at 30 September 2022		14,571	600	2,344	17,515
Balance as 1 April 2021		14,163	408	1,869	16,440
<b>Profit for the financial year</b>		-	-	2,173	2,173
<b>Total comprehensive income for the financial year</b>		-	-	2,173	2,173
<b>Contributions by and distributions to owners</b>					
Share-based payments		-	-	-	-
Dividends		-	-	(1,102)	(1,102)
<b>Total transactions with owners</b>		-	-	(1,102)	(1,102)
Balance at 30 September 2021		14,163	408	2,940	17,511

E. Condensed interim consolidated statement of cash flows

Note	Group	
	30 September 2022	30 September 2021
	S\$'000	S\$'000
<b>Operating activities</b>		
Profit before income tax	919	2,288
Adjustments for:		
Amortisation of intangible assets	84	46
Depreciation of plant and equipment	56	29
Depreciation of right-of-use assets	261	225
Loss allowance on trade receivables	18	20
Bad debt recovered	(104)	(146)
Fair value gain on financial assets at FVTPL	614	(717)
Interest income	(1)	(15)
Interest expense	35	45
Gain on lease termination	-	(16)
Loss on disposal of financial asset at FVTPL	-	34
Loss on disposal of plant and equipment	-	5
Dividend income from financial assets at FVTPL	(104)	(12)
Rental rebate	-	-
Provisions	-	(1)
Share of results of joint venture	(70)	(10)
Operating cash flows before working capital changes	1,707	1,775
Working capital changes:		
Inventories	15	153
Trade and other receivables	665	(150)
Prepayments	263	5
Trade and other payables	(367)	(640)
Cash generated from operations	2,283	1,143
Income tax paid	(201)	(157)
Net cash from operating activities	2,082	986

E. Condensed interim consolidated statement of cash flows

Note	Group 6 months ended	
	30 September 2022	30 September 2021
	S\$'000	S\$'000
<b>Investing activities</b>		
Acquisition of subsidiaries, net of cash acquired (Carlin Management Services Pte. Ltd.)	(2,395)	-
Purchase of plant and equipment	(30)	(46)
Dividend income from financial assets at FVTPL	104	12
Investment in financial assets at FVTPL, net	-	376
Net cash (used in)/from investing activities	(2,321)	342
<b>Financing activities</b>		
Dividends paid to owners of company	(1,115)	(1,102)
Dividends paid to non-controlling interest	-	(135)
Repayment of principal portion of lease liabilities/finance lease payables	(267)	(228)
Repayments of interest portion of lease liabilities/finance lease payables	(14)	(14)
Repayment of bank borrowings	(273)	-
Interest paid	-	(25)
Proceeds from bank borrowings	-	2,500
Advances to joint venture	-	(25)
Net cash from/(used in) financing activities	(1,669)	971
Net change in cash and cash equivalents	(1,908)	2,299
Cash and cash equivalents at beginning of financial period	6,339	6,658
Effect of foreign exchange rate changes on cash and cash equivalents	2	(6)
Cash and cash equivalents at end of financial period	4,433	8,951

## F. Notes to the condensed interim consolidated financial statements

### 1. Corporate information

Medinex Limited (the “**Company**”) is a public limited company incorporated and domiciled in Singapore. The Company was listed on the Catalist Board of the Singapore Exchange Securities Trading Limited (the “**SGX-ST**”) on 7 December 2018. These condensed interim consolidated financial statements as at and for the six months ended 30 September 2022 comprise the Company and its subsidiaries (collectively, the “**Group**”). The primary activity of the Company is that of an investment holding company.

The principal activities of the Group are:

- (a) providing business support services;
- (b) providing medical support services; and
- (c) providing pharmaceutical services

### 2. Basis of Preparation

The condensed interim financial statements for the six months ended 30 September 2022 have been prepared in accordance with SFRS(I) 1-34 Interim Financial Reporting issued by the Accounting Standards Council Singapore. The condensed interim financial statements do not include all the information required for a complete set of financial statements. However, selected explanatory notes are included to explain events and transactions that are significant to an understanding of the changes in the Group’s financial position and performance of the Group since the last annual financial statements for the year ended 31 March 2022.

The accounting policies adopted are consistent with those of the previous financial year which were prepared in accordance with SFRS(I)s, except for the adoption of new and amended standards as set out in Note 2.1.

The condensed interim financial statements are presented in Singapore dollar which is the Company’s functional currency.

#### 2.1. New and amended standards adopted by the Group

A number of amendments to Standards have become applicable for the current reporting period. The Group did not have to change its accounting policies or make retrospective adjustments as a result of adopting those standards.

#### 2.2. Use of judgements and estimates

In preparing the condensed interim financial statements, management has made judgements, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets and liabilities, income and expense. Actual results may differ from these estimates.

## F. Notes to the condensed interim consolidated financial statements (cont'd)

### 2. Basis of Preparation (cont'd)

#### 2.2. Use of judgements and estimates (cont'd)

The significant judgements made by management in applying the Group's accounting policies and the key sources of estimation uncertainty were the same as those that applied to the consolidated financial statements as at and for the year ended 31 March 2022.

Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimates are revised and in any future periods affected.

Information about critical judgements in applying accounting policies that have the most significant effect on the amounts recognised in the financial statements is included in the following notes:

- Note 10 - Classification of equity investments

Information about assumptions and estimation uncertainties that have a significant risk of resulting in a material adjustment to the carrying amounts of assets and liabilities within the next interim period are included in the following notes:

- Note 11 - impairment test of intangible assets and goodwill: key assumptions underlying recoverable amounts

### 3. Seasonal operations

The Group's businesses are not affected significantly by seasonal or cyclical factors during the financial period.

### 4. Segment and revenue information

The Group is organised into the following main business segments:

- Segment 1: Medical support services
- Segment 2: Business support services
- Segment 3: Pharmaceutical
- Segment 4: Medical services

F. Notes to the condensed interim consolidated financial statements (cont'd)

4. Segment and revenue information (cont'd)

4.1. Reportable segments

Business segment	Medical support services	Business support services	Pharmaceutical services	Medical services	Unallocated Expenses	Consolidated
1 April 2022 to 30 September 2022	(\$\$'000)	(\$\$'000)	(\$\$'000)	(\$\$'000)	(\$\$'000)	(\$\$'000)
<b>Revenue</b>						
External revenue	1,913	1,836	1,903	833	1	6,486
<b>Profit from operations</b>						
Share of results from joint ventures, net of tax	-	-	-	-	70	70
Interest income	-	-	-	-	1	1
Inventories and consumables used	2	-	1,609	192	-	1,803
Finance costs	15	2	12	5	1	35
Amortisation and depreciation expense	120	36	40	110	95	401
Employee benefits expense	355	395	191	357	1,247	2,545
Income tax expense	98	70	-	32	8	208
Reportable segment profit before income tax	1,385	1,141	27	178	(1,812)	919
		-			-	
Net profit for the financial year after tax	1,287	1,071	27	146	(1,820)	711

F. Notes to the condensed interim consolidated financial statements (cont'd)

4. Segment and revenue information (cont'd)

4.1. Reportable segments (cont'd)

Business segment	Medical support services	Business support services	Pharmaceutical services	Medical services	Unallocated Expenses	Consolidated
<b>1 April 2021 to 30 September 2021</b>	<b>(S\$'000)</b>	<b>(S\$'000)</b>	<b>(S\$'000)</b>	<b>(S\$'000)</b>	<b>(S\$'000)</b>	<b>(S\$'000)</b>
<b>Revenue</b>						
External revenue	1,848	1,241	1,706	951	60	5,806
<b>Profit from operations</b>						
Share of results from joint ventures, net of tax	-	-	-	-	10	10
Interest income	-	-	-	-	16	16
Inventories and consumables used	10	-	1,454	227		1,691
Finance costs	30	-	3	11	1	45
Amortisation and depreciation expense	69	14	24	129	63	299
Employee benefits expense	287	26	287	413	1,035	2,048
Income tax expense	100	74	(3)	21	-	192
Reportable segment profit before income tax	1,465	1,063	(27)	167	(380)	2,288
Net profit for the financial year after tax	1,365	989	(24)	146	(380)	2,096



F. Notes to the condensed interim consolidated financial statements (cont'd)

4. Segment and revenue information (cont'd)

4.1. Reportable segments (cont'd)

Business segment	Medical support services	Business support services	Pharmaceutical services	Medical services	Unallocated Expenses	Consolidated
<b>1 April 2022 to 30 September 2022</b>	<b>(S\$'000)</b>	<b>(S\$'000)</b>	<b>(S\$'000)</b>	<b>(S\$'000)</b>	<b>(S\$'000)</b>	<b>(S\$'000)</b>
<u>Other information:</u>						
Additions to non-current assets						
-plant and equipment	2	17	2	-	9	30
-intangible assets	-	2,995	-	-	-	2,995
-right-of-use assets	197	172	-	-	-	369
Segment assets	749	1,669	3,253	943	16,037	22,651
Segment liabilities	1,711	577	1,521	510	665	4,984
<b>1 April 2021 to 30 September 2021</b>						
<u>Other information:</u>						
Additions to non-current assets						
-plant and equipment	19	-	19	1	1	40
-intangible assets	-	-	-	-	-	-
-right-of-use assets	(215)	-	(215)	-	-	(430)
Segment assets	3,707	1,397	3,798	1,106	15,702	25,710
Segment liabilities	4,431	401	1,885	739	474	7,930

F. Notes to the condensed interim consolidated financial statements (cont'd)

4. Segment and revenue information (cont'd)

4.2. Disaggregation of Revenue

Business segment	Medical support services		Business support services		Pharmaceutical services		Medical services		Total	
	01 April 2022 to 30 September 2022	01 April 2021 to 30 September 2021	01 April 2022 to 30 September 2022	01 April 2021 to 30 September 2021	01 April 2022 to 30 September 2022	01 April 2021 to 30 September 2021	01 April 2022 to 30 September 2022	01 April 2021 to 30 September 2021	01 April 2022 to 30 September 2022	01 April 2021 to 30 September 2021
	(\$\$'000)	(\$\$'000)	(\$\$'000)	(\$\$'000)	(\$\$'000)	(\$\$'000)	(\$\$'000)	(\$\$'000)	(\$\$'000)	(\$\$'000)
Type of good or services										
Service fee	1,913	1,848	1,836	1,241	-	-	-	-	3,749	3,089
Sale of medical and pharmaceutical products	-	-	-	-	1,903	1,706	-	-	1,903	1,706
Provision of medical services	-	-	-	-			834	951	834	951
	<u>1,913</u>	<u>1,848</u>	<u>1,836</u>	<u>1,241</u>	<u>1,903</u>	<u>1,706</u>	<u>834</u>	<u>951</u>	<u>6,486</u>	<u>5,746</u>
Timing of transfer of goods and services										
Point in time	1,856	1,788	1,701	1,165	1,903	1,706	834	951	6,294	5,610
Over time	57	60	134	76	-	-	-	-	192	136
	<u>1,913</u>	<u>1,848</u>	<u>1,836</u>	<u>1,241</u>	<u>1,903</u>	<u>1,706</u>	<u>834</u>	<u>951</u>	<u>6,486</u>	<u>5,746</u>

## Geographical information

The Group's operations are primarily carried out in Singapore. Accordingly, no geographical segment assets and revenue from external customers' information are presented.

### F. Notes to the condensed interim consolidated financial statements (cont'd)

#### 5. Financial assets and financial liabilities

Set out below is an overview of the financial assets and financial liabilities of the Group as at 30 September 2022 and 31 March 2022:

	Group		Company	
	30-Sep-22	31-Mar-22	30-Sep-22	31-Mar-22
	S\$'000	S\$'000	S\$'000	S\$'000
<b>Financial assets</b>				
Trade and other receivables	1,587	2,121	389	207
Cash and bank balances	3,917	5,823	825	3,067
Investment in subsidiaries	-	-	13,597	10,597
Investment in joint venture	-	208	195	195
At fair value through profit or loss	4,959	5,573	4,959	5,573
<b>Financial liabilities</b>				
Trade and other payables	1,333	1,470	1,132	2,720
Lease liabilities	920	830	-	-
Bank borrowings	2,023	2,275	-	10

F. Notes to the condensed interim consolidated financial statements (cont'd)

6. Profit before taxation

6.1. Significant items

	30-Sep-22 (6 months) S\$'000	30-Sep-21 (6 months) S\$'000
<b>Profit for the financial period/year is stated after charging the following:</b>		
Fair value (gain)/loss on financial asset at fair value through profit or loss ("FVTPL")	614	(717)
Rental income	-	(3)
Government grant	(164)	(165)
Interest income	(1)	(15)
Loss allowance on trade receivables	18	20
Amortisation of intangible assets	84	46
Depreciation of plant and equipment	56	29
Depreciation of right-of-use assets	261	225
Cost of service	148	76
Platform fees	69	56
Professional fees	25	-

**F. Notes to the condensed interim consolidated financial statements (cont'd)**

**7. Taxation**

The Group calculates the period income tax expense using the tax rate that would be applicable to the expected total annual earnings. The major components of income tax expense in the condensed interim consolidated statement of profit or loss are:

	Period from 1 April 2022 to 30 September 2022 S\$'000	Period from 1 April 2021 to 30 September 2021 S\$'000
Current income tax		
- current financial period	208	192
Deferred tax		
- current financial period	-	-
Total income tax expense recognised in profit or loss	208	192

**8. Dividends**

	Group	
	Period from 1 April 2022 to 30 September 2022 S\$'000	Period from 1 April 2021 to 30 September 2021 S\$'000
Final tax exempt dividend of \$0.0084 per ordinary share for the financial year ended 31 March 2022	1,114	1,102
	1,114	1,102

F. Notes to the condensed interim consolidated financial statements (cont'd)

9. Earnings Per Share

The calculation for earnings per share is based on:

	Group Half Year Ended	
	30-Sept-22 (Unaudited) S\$'000	30-Sept-21 (Unaudited) S\$'000
Profit attributable to owners of the parent (\$)	661,000	2,052,000
Weighted-average number of ordinary shares used in issue during the financial year/period applicable to earnings per share	132,691,176	131,207,540
<i>Earnings per share (in cents)</i>		
- Basic and diluted	0.50	1.56

The calculations of basic and diluted earnings per share are based on profit attributable to owners of the parent divided by the weighted average number of ordinary shares outstanding during the financial year/period.

The Group did not have any dilutive potential ordinary shares as at 30 September 2022 and 30 September 2021.

10. Net Asset Value

	Group		Company	
	30-Sep-22 (Unaudited)	31-Mar-22 (Audited)	30-Sep-22 (Unaudited)	31-Mar-22 (Audited)
<b>Net asset value ("NAV")</b>				
NAV (S\$) <sup>(1)</sup>	17,394,000	17,253,000	17,515,000	17,373,000
Number of ordinary shares in issue	132,691,176	131,207,540	132,691,176	131,207,540
NAV per ordinary share (S\$ cents)	13.31	13.15	13.20	13.24

Note:

(1) Based on equity attributable to owners of the parent.

**F. Notes to the condensed interim consolidated financial statements (cont'd)**

**11. Financial assets at fair value through profit and loss**

Financial assets at fair value through profit and loss comprise the following:

	<b>Group and Company</b>	
	<b>30 Sep 2022</b>	<b>31 Mar 2022</b>
	<b>S\$'000</b>	<b>S\$'000</b>
Balance at beginning of financial year	5,573	4,321
Fair value (loss)/gain	(614)	387
Gain on derecognition	-	471
Addition	-	1,284
Disposal	-	(856)
(Loss)/Gain on disposal	-	(34)
Balance at end of financial year	4,959	5,573

The instruments are all mandatorily measured at fair value through profit or loss.

**11.1. Fair value measurement**

The Group classifies financial assets measured at fair value using a fair value hierarchy which reflects the significance of the inputs used in making the measurements. The fair value hierarchy has the following levels:

- a) Quoted prices (unadjusted) in active markets for identical assets or liabilities (Level 1);
- b) Inputs other than quoted prices included within Level 1 which are observable for the asset or liability, either directly (i.e. as prices) or indirectly (i.e. derived from prices) (Level 2); and
- c) Inputs for the assets or liability which are not based on observable market data (unobservable inputs) (Level 3)

**Fair value measurements using**

	<u>Level 1</u>	<u>Level 2</u>	<u>Level 3</u>	<u>Total</u>
	<b>S\$'000</b>	<b>S\$'000</b>	<b>S\$'000</b>	<b>S\$'000</b>
<b>Group</b>				
<b>2022</b>				
<b><u>Financial assets</u></b>				
Financial assets, at FVTPL				
- Quoted equity securities	3,701	-	-	3,701
- Unquoted equity investments	-	-	1,258	1,258
	3,701	-	1,258	4,959
<b>2021</b>				
<b><u>Financial assets</u></b>				
Financial assets, at FVTPL				
- Quoted equity securities	4,315	-	-	4,315
- Unquoted equity securities	-	-	1,258	1,258
	4,315	-	1,258	5,573

F. Notes to the condensed interim consolidated financial statements (cont'd)

12. Intangible assets

	Customer listing	Goodwill	Software	Web Development	Total
	S\$'000	S\$'000	S\$'000	S\$'000	S\$'000
Group					
Cost					
Balance at 1 April 2022	430	6,844	27	6	7,307
Additions	278	2,717	-	-	2,995
Balance at 30 September 2022	<u>708</u>	<u>9,561</u>	<u>27</u>	<u>6</u>	<u>10,302</u>
Accumulated amortisation and impairment loss					
Balance at 1 April 2022	271	339	9	2	621
Amortisation for the financial year	79	-	4	1	84
Impairment loss for financial year	-	-	-	-	-
Balance at 30 September 2022	<u>350</u>	<u>339</u>	<u>13</u>	<u>3</u>	<u>705</u>
Net carrying amount					
Balance at 30 September 2022	<u>358</u>	<u>9,222</u>	<u>14</u>	<u>3</u>	<u>9,597</u>
Remaining useful life at end of financial year	<u>1-5 years</u>	<u>Indefinite</u>	<u>2 years</u>	<u>3 years</u>	



F. Notes to the condensed interim consolidated financial statements (cont'd)

12. Intangible assets (cont'd)

	Customer listing	Goodwill	Software	Web Development	Total
	S\$'000	S\$'000	S\$'000	S\$'000	S\$'000
Group					
Cost					
Balance at 1 April 2021	430	6,844	-	6	7,280
Additions	-	-	27	-	27
Balance at 31 March 2022	430	6,844	27	6	7,307
Accumulated amortisation and impairment loss					
Balance at 1 April 2021	181	-	-	1	182
Amortisation for the financial year	90	-	9	1	100
Impairment loss for financial year	-	339	-	-	339
Balance at 31 March 2022	271	339	9	2	621
Net carrying amount					
Balance at 31 March 2022	159	6,505	18	4	6,686
Remaining useful life at end of financial year	1-5 years	Indefinite	2 years	3 years	

F. Notes to the condensed interim consolidated financial statements (cont'd)

13. Plant and equipment

During the six months ended 30 September 2022, the Group acquired assets amounting to \$30,227 (30 September 2021: \$45,967).

14. Borrowings

	Group		Company	
	30 September 2022 S\$'000	31 March 2022 S\$'000	30 September 2022 S\$'000	31 March 2022 S\$'000
<b>Non-current</b>				
<i>Unsecured</i>				
Term loan I	-	-	-	-
Term loan II	1,527	1,779	-	-
	<u>1,527</u>	<u>1,779</u>	-	-
<b>Current</b>				
<i>Unsecured</i>				
Term loan I	-	-	-	-
Term loan II	496	486	-	-
Revolving working capital line	-	10	-	10
	<u>496</u>	<u>496</u>	-	10
	<u>2,023</u>	<u>2,275</u>	-	10

Revolving working capital line is repayable on demand, unsecured and is arranged at floating rates.

Term loan is arranged at fixed rate and is repayable within over 60 months. It is supported by corporate guarantee provided by the Company. The carrying amount of the Group's non-current term loans approximate their fair values as the current lending rates for similar types of lending arrangements are not materially different from the rates obtained by the Group.

## F. Notes to the condensed interim consolidated financial statements (cont'd)

### 15. Related Party Transactions

There are no material related party transactions apart from those disclosed elsewhere in the financial statements.

### 16. Share Capital

	Group and Company			
	30 September 2022	31 March 2022	30 September 2022	31 March 2022
	Number of ordinary shares		\$	\$
<b>Issued and fully-paid:</b>				
Balance at beginning of financial year/period	131,207,540	131,207,540	14,163,317	14,163,317
Issue of new shares	1,483,636	-	408,000	-
Balance at end of financial year/period	132,691,176	131,207,540	14,571,317	14,163,317

The Company announced on 19 July 2022 that the vendor of Ark Leadership & Learning Pte Ltd (“ARK”) had fulfilled the guaranteed profit of no less than S\$576,000 for the three-year period commencing from 1 April 2019. Accordingly, 1,483,636 consideration shares had been allotted and issued to the Vendor, at an issue price of S\$0.275 per share (the “**Consideration Shares**”).

Following the allotment and issuance of the Consideration Shares, the total number of issued and paid-up ordinary shares (excluding treasury shares) of the Company has increased from 131,207,540 to 132,691,176.

There were no convertibles, treasury shares or subsidiary holdings as at 30 September 2022 and 30 September 2021.

The Company did not have any sale, transfer, cancellation and/or use of treasury shares or subsidiary holdings during the six-month period ended and as at 30 September 2022.

### 17. Subsequent events

There are no known subsequent events which have led to adjustments to this set of interim financial statements.

## G. Other information required pursuant to Appendix 7C of the Catalist Rules

### 1. Whether the figures have been audited, or reviewed and in accordance with which auditing standard or practice.

The condensed consolidated statement of financial position of Medinex Limited and its subsidiaries as at 30 September 2022 and the related condensed consolidated profit or loss and other comprehensive income, condensed consolidated statement of changes in equity and condensed consolidated statement of cash flows for the six-month period then ended and certain explanatory notes have not been audited or reviewed.

### 2. A review of the performance of the group, to the extent necessary for a reasonable understanding of the group's business. It must include a discussion of the following:

- (a) any significant factors that affected the turnover, costs, and earnings of the group for the current financial year reported on, including (where applicable) seasonal or cyclical factors; and
- (b) any material factors that affected the cash flow, working capital, assets or liabilities of the group during the current financial year reported on

Review for the performance of the Group for the six months ended 30 September 2022 ("HY2023") as compared to the six months ended 30 September 2021 ("HY2022")

#### CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME

##### Revenue

The Group recorded an increase in revenue of approximately S\$0.68 million or approximately 11.72% for HY2023 as compared to HY2022. The growth in HY2023 was attributable to the increase in (a) pharmaceutical sale contributed by Nex Healthcare Pte. Ltd. of approximately S\$0.2 million, (b) accounting fee of approximately S\$0.3 million, (c) secretary fee of approximately S\$0.1 million, (d) tax fee of approximately \$0.08 million, and (e) service fee of approximately S\$0.12 million, and partially offset by decrease in medical services provided by Sen Med Pte. Ltd. and its subsidiaries of approximately S\$0.12 million.

##### Other items of income

Other income, comprising mainly fixed deposits interest, government grants, fair value gain on financial asset at FVTPL, commission income and rental income, decreased by approximately S\$0.68 million mainly due to the decrease in (a) bad debt recovered of approximately S\$0.04 million, (b) fair value gain on financial asset at FVTPL of approximately S\$0.72 million, partially offset by the increase in dividend income of approximately S\$0.08 million.

##### Items of expenses

Inventories and consumables used and changes in inventories increased by approximately S\$0.11 million or approximately 6.62% due to the increase in demand for pharmaceutical products.

Employee benefits expense increased by S\$0.5 million, or approximately 24.25% due to additional headcounts arising from a new subsidiary, Carlin Management Services Pte Ltd ("CMS"), new set-up of Medinex Specialist Centre and subsidiary company in Malaysia.

Amortisation and depreciation expenses increased by approximately S\$0.1 million or approximately 34.26% in HY2023 as compared to HY2022 mainly due to the increase in (a) depreciation of plant and equipment of approximately S\$0.03 million due to the increase in plant and equipment during HY2023, (b) amortisation of intangible assets of approximately S\$ 0.04 due to the increase in customer relationship and goodwill for the acquisition of new subsidiary, CMS, and (c) depreciation of right-of-use assets of approximately S\$ 0.03 due to renewal of new lease.

Other expenses increased by approximately S\$0.73 million or approximately 148.59% in HY2023,

mainly due to the increase in (a) fair value loss on financial assets at FVTPL of approximately S\$0.61 million, (b) cost of sales of approximately S\$0.03 million, (c) legal & professional fee of approximately S\$0.06 million, and (d) entertainment of approximately S\$0.03 million.

Finance cost decreased by approximately S\$0.01 million or approximately 21.03% due to the lower loan amount in HY2023.

Share of results of joint venture, net of tax increased by approximately S\$0.06 million or 615.83% due to the higher share of profit of investment in Healthcare Essentials Pte. Ltd. (“HEPL”) in HY2023.

#### Profit before income tax

As a result of the abovementioned, profit before income tax decreased by approximately S\$1.39 million or approximately 66.10%.

#### Income tax expense

Income tax expenses increased by approximately S\$0.01 million or approximately 8.50% despite a decrease in the profit before income tax as the fair value gain on investment in financial asset at FVTPL was not taxable.

### **CONSOLIDATED STATEMENT OF FINANCIAL POSITION**

**The comparative performance for both the assets and liabilities are based on the Group’s financial statements as at 30 September 2022 and 31 March 2022 (“FY2022”).**

#### Non-current assets

The Group’s non-current assets mainly relates to plant and equipment, right-of-use assets, intangible assets, investment in joint venture and financial assets at FVTPL.

The Group’s intangible assets increased by approximately S\$2.91 million due to acquisition of a new subsidiary, CMS with a goodwill of approximately S\$2.71 million, and customer relationships intangible assets of approximately S\$0.28 million which were partially offset by the amortisation of intangible assets of the Company’s subsidiaries, ARK, Medinex Advisory Pte Ltd, Medinex Professional Services Pte Ltd and CMS of approximately S\$0.08 million.

The Group’s investment in joint venture increased by approximately S\$0.07 million due to share of profit from HEPL.

The Group’s right-of-use assets increased by approximately S\$0.10 million due to entering into new lease agreements of approximately S\$0.36 million and partially offset by depreciation of approximately S\$0.26 million.

The Group’s plant and equipment decreased by approximately S\$0.03 million mainly due to the depreciation of approximately S\$0.06 million and partially offset by renovation of approximately S\$0.03 million.

Financial assets at FVTPL decreased by approximately S\$0.61 million due to fair value losses on financial assets at FVTPL.

#### Current assets

Inventories decreased by approximately S\$0.01 million which was in line with the increased sale of pharmaceutical products.

Trade and other receivables decreased by approximately S\$0.53 million due to additional measures of credit control implemented by the group.

Contract assets decreased by approximately S\$0.04 million due to decrease of accrued revenue of the Company's subsidiary, ARK.

Prepayments decreased by approximately S\$0.27 million mainly due to decrease of deposit paid for acquisition of CMS.

#### Non-current liabilities

The Group recorded an increase in lease liabilities of approximately S\$0.08 million due to entering into new lease agreements and offset by lease repayment during HY2023.

The Group's borrowings decreased by approximately S\$0.25 million due to the bank loan repayment during HY2023.

#### Current liabilities

Trade and other payables decreased by approximately S\$0.14 million mainly due to decreased payables arising from the decrease in (a) trade payables in HY2023 of approximately S\$0.06 million, (b) goods and services tax payable of approximately S\$0.06 million, (c) other accruals of approximately S\$0.34 million incurred in FY2022, and (d) other creditors of approximately S\$0.06 million and offset by increase in dividend payable S\$0.38 million.

The Group recorded an increase in lease liabilities of approximately S\$0.08 million due to the entry into new lease agreements and offset by lease repayment during HY2023.

Contract liabilities decreased by approximately S\$0.23 million mainly due to the decrease in advanced payment received from customers of approximately S\$0.09 million and the deferred income of approximately S\$0.14 million.

The increase in current income tax payables of approximately S\$0.01 million was due to higher taxable profit despite a decrease of fair value gain on investment in financial asset at FVTPL in HY2023 which was not taxable.

#### Equity

Share capital increased approximately S\$0.41 million due to allotment and issue of consideration shares in relation to the acquisition of ARK.

Other reserves increased approximately S\$0.19 million due to the acquisition of new subsidiary, CMS.

The retained earnings decreased by S\$0.45 million mainly due to profit earned of approximately S\$0.66 million and partially offset by the dividend payment of approximately S\$1.11 million in HY2023.

#### CONSOLIDATED STATEMENT OF CASH FLOWS

The Group recorded a net cash generated from operating activities of approximately S\$2.08 million in HY2023, mainly due to operating cash flow before changes in working capital of approximately S\$1.71 million and adjusted for net working capital inflow of approximately S\$0.57 million and income tax paid of S\$0.20 million. The net working capital inflow was mainly due to (i) decrease in trade and other receivables of approximately S\$0.66 million, (ii) decrease in inventory of approximately S\$0.01 million and (iii) decrease in prepayments of approximately S\$0.26 million and

partially offset by decrease in trade and other payables of approximately S\$0.37 million

Net cash used in investing activities of approximately S\$2.32 million in HY2023 was mainly due to (a) acquisition of CMS of approximately S\$2.4 million and (b) purchase of plant and equipment of approximately S\$ 0.03 million, and partially offset by dividend income from financial asset at FVTPL of approximately S\$0.11 million.

Net cash used in financing activities amounted to approximately S\$1.67 million in HY2023 was mainly due to (a) dividend payout to shareholders of the Company of approximately S\$1.11 million, (b) repayment of bank loan of approximately S\$0.28 million, and (c) repayment of principal and interest portion of lease liabilities of approximately S\$0.28 million.

As a result of the abovementioned, the Group recorded a net decrease in cash and cash equivalent of approximately S\$1.91 million in HY2023, mainly due to acquisition of CMS.

**Where a forecast, or a prospect statement, has been previously disclosed to shareholders, any variance between it and the actual results**

Not applicable as no forecast or prospect statement has been made or disclosed previously.

**A commentary at the date of the announcement of the significant trends and competitive conditions of the industry in which the group operates and any known factors or events that may affect the group in the next reporting period and the next 12 months.**

The Group successfully acquired CMS on 1 April 2022 which provides the Group the opportunity to bring its business support services to the new customer segments.

The Company's subsidiary, Sen Med Holding Pte. Ltd. ("**Sen Med**"), has relocated 2 of its clinics to the new premises. Renovation is currently in progress and expected to be completed by January 2023. New management team was appointed to revamp the operation and improve the effectiveness and efficiency of Sen Med.

For HY2023, the Group continued to face an uncertain and challenging business environment. The conflict between Russia and Ukraine has had an immersive and deep impact upon many facades of the global economy and societies. The business costs in many sectors have risen due to the disruptions in supply of raw materials, especially oil and gas. We will continue to monitor the impact of the conflict on our clients' businesses and provide services in response to their needs.

The Company will continue to develop the new stream of services, particularly in clinic set-up support, information technology, digital marketing & branding, human resources support services and financial management support services to pursue long-term and sustainable growth.

### 3. Dividend

If a decision regarding dividend has been made: -

- (a) Whether an interim (final) ordinary dividend has been declared (recommended); and

Yes

Name of Dividend	Interim
Dividend Type	Ordinary
Dividend Amount per Share (in S\$ cents)	0.65 cents per ordinary share (one tier tax)
Tax Rate	Tax exempt

The distribution of the interim dividends represented approximately 131% of the Group's net profit after tax attributable to Shareholders for the financial period from 1 April 2022 to 30 September 2022.

- (b) (i) Amount per share (cents)

Please refer to paragraph 3(a).

- (ii) Previous corresponding period (cents)

Name of Dividend	Interim
Dividend Type	Ordinary
Dividend Amount per Share (in S\$ cents)	0.84 cents per ordinary share (one tier tax)
Tax Rate	Tax exempt

- (c) Whether the dividend is before tax, net of tax or tax exempt. If before tax or net of tax, state the tax rate and the country where the dividend is derived. (if the dividend is not taxable in the hands of shareholders, this must be stated.)

Please refer to paragraph 3(a).

- (d) The date the dividend is payable.

The dividend will be paid on 18 January 2023.

- (e) The date on which Registrable Transfers received by the Company (up to 5.00pm) will be registered before entitlements to the dividend are determined.

Notice is hereby given that the Share Transfer Books and the Register of Members of the Company will be closed at 5.00 p.m. on 5 January 2023 for the purpose of determining shareholders' entitlements to the interim dividend.

Duly completed transfers of shares received by the Company's Share Registrar, Tricor Barbinder Share Registration Services (A division of Tricor Singapore Pte. Ltd.) at 80 Robinson Road, #02-00, Singapore 068898, up to 5.00 p.m. on 5 January 2023 will be registered to determine shareholders' entitlements to the interim dividend.

Shareholders (being depositors) whose securities accounts with The Central Depository (Pte) Limited are credited with shares as at 5.00 p.m. on 5 January 2023 will be entitled to the interim dividend.



#### 4. Interested Party Transactions

The Company does not have a general mandate from shareholders for interested person transactions.

The Company confirms that there were no IPT transactions of more than S\$100,000 in HY2023.

#### 5. Use of IPO Proceeds

The Company refers to the net cash proceeds amounting to S\$5.28 million (excluding cash listing expenses of approximately S\$1.22 million) raised from the IPO on the Catalist Board of SGX-ST on 7 December 2018.

As at the date of this announcement, the status on the use of the IPO net proceeds is as follows:

	Amount allocated (S\$'000)	Amount utilised (S\$'000)	Balance (S\$'000)
Expand our Group's business operations via acquisitions, joint ventures and/or strategic partnerships	4,000.00	3,532.50 <sup>(1)</sup>	467.50
Working Capital	1,316.00	786.00 <sup>(2)</sup>	530.00
Total	5,316.00	4,318.50	997.50

**Notes:**

- (1) Utilised for the following:-  
(a) acquisition of Sen Med. - S\$1,732,500;  
(b) acquisition of ARK - S\$600,000; and  
(c) acquisition of SKIC and Medinex Advisory – S\$1,200,000.
- (2) Utilised for the payment of listing expenses of S\$36,000 and the provision of the convertible loan amount of S\$750,000 to Singapore Paincare Holdings Limited.

The utilisation is in accordance with the intended use as stated in the Company's offer document dated 30 November 2018.

#### 6. Confirmation that the issuer has procured undertaking from all its directors and executive officers (in the format set out in Appendix 7H) under Rule 720(1)

The Company confirms that it has procured undertaking from all its directors and executive officers (in the format as set out in Appendix 7H) under Rule 720(1) of the Catalist Rules.

## 7. Negative Confirmation by the Board pursuant to Rule 705(5) of the Catalist Rules

On behalf of the Board of Directors of the Company, we, the undersigned, hereby confirm to the best of our knowledge that nothing has come to the attention of the Board of Directors of the Company which may render the financial statements for the six-month period ended 30 September 2022 to be false or misleading in any material aspect.

### BY ORDER OF THE BOARD

Jessie Low Mui Choo  
Executive Director and Chief Executive Officer

Tan Lee Meng  
Non-Executive Chairman

Singapore  
14 November 2022

*This announcement has been prepared by the Company and reviewed by the Company's Sponsor, Novus Corporate Finance Pte. Ltd. (the "Sponsor"), in compliance with Rule 226(2)(b) of the Singapore Exchange Securities Trading Limited ("SGX-ST") Listing Manual Section B: Rules of Catalist.*

*This announcement has not been examined or approved by the SGX-ST and the SGX-ST assumes no responsibility for the contents of this announcement including the correctness of any of the statements or opinions made, or reports contained in this announcement.*

*The contact person for the Sponsor is Mr. Pong Chen Yih, Chief Operating Officer, at 7 Temasek Boulevard, #18-03B Suntec Tower 1, Singapore 038987, telephone (65) 6950 2188.*